Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 04/08/2024 at 07:00, 2 years 3 months ago

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals presented data from study 014/015 and evenamide clinical development outlook at SIRS 2024 Congress, showcasing potential for new TRS treatment options

Clinical Development Newron Pharmaceuticals Evenamide Study 014/015 Schizophrenia International Research Society
BRIEF

published on 03/19/2024 at 07:05, 2 years 3 months ago

Newron Pharmaceuticals S.p.A. Announces 2023 Financial Results and Provides Outlook for 2024

2024 Outlook Financial Results 2023 Newron Pharmaceuticals Evenamide Development Xadago Safinamide
BRIEF

published on 03/19/2024 at 07:05, 2 years 3 months ago

Newron Pharmaceuticals SpA annonce ses résultats financiers pour 2023 et fournit des perspectives pour 2024

Perspectives 2024 Résultats Financiers 2023 Produits Pharmaceutiques Newron Xadago Safinamide Développement D'Evenamide
PRESS RELEASE

published on 03/19/2024 at 07:00, 2 years 3 months ago

Newron presents 2023 financial results and provides 2024 outlook
Newron Pharmaceuticals S.p.A. presents 2023 financial results and 2024 outlook, including advancements in schizophrenia treatment and strategic partnerships

Financial Results 2024 Outlook Partnerships Newron Pharmaceuticals Schizophrenia Treatment
BRIEF

published on 03/15/2024 at 07:05, 2 years 4 months ago

Newron Pharmaceuticals S.p.A. Announces Amended Repayment Agreement with European Investment Bank

European Investment Bank Newron Pharmaceuticals Financing Agreement Evenamide CNS Treatments
BRIEF

published on 03/15/2024 at 07:05, 2 years 4 months ago

Newron Pharmaceuticals SpA annonce un accord de remboursement modifié avec la Banque européenne d'investissement

Produits Pharmaceutiques Newron Evenamide Banque Européenne D'investissement Accord De Financement Traitements Du SNC
PRESS RELEASE

published on 03/15/2024 at 07:00, 2 years 4 months ago

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Newron Pharmaceuticals S.p.A. agrees with EIB to extend repayment dates of 2018 financing agreement tranches after pipeline milestones

European Investment Bank Financing Agreement Evenamide Newron Pharmaceuticals S.p.A. Loan Repayment Dates
BRIEF

published on 03/14/2024 at 18:37, 2 years 4 months ago

Newron Pharmaceuticals Secures Up to EUR 15 Million in Funding Through New Share Issuance

Share Issuance Biopharmaceuticals Investment Agreement Newron Pharmaceuticals CNS Therapies
BRIEF

published on 03/14/2024 at 18:37, 2 years 4 months ago

Newron Pharmaceuticals obtient jusqu'à 15 millions d'euros de financement grâce à l'émission de nouvelles actions

Émission D'actions Produits Biopharmaceutiques Accord D'investissement Produits Pharmaceutiques Newron Thérapies Du SNC
PRESS RELEASE

published on 03/14/2024 at 18:32, 2 years 4 months ago

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Newron Pharmaceuticals S.p.A. enters a subscription agreement for up to 2.05 million new shares, aiming to raise EUR 15.0 million. The investment supports CNS therapies development

Subscription Agreement Newron Pharmaceuticals Newly Issued Shares EUR 15.0 Million CNS Therapies Development

Published on 07/17/2026 at 01:00, 2 hours 37 minutes ago

RJK Explorations Ltd. Announces Closing of Private Placement for Gross Proceeds of $310,000
Published on 07/17/2026 at 00:00, 3 hours 37 minutes ago

LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
Published on 07/16/2026 at 16:21, 11 hours 16 minutes ago

First Canadian Graphite Completes Phase I Exploration on Zone 13 Discovery and Expands Lands Package
Published on 07/16/2026 at 15:30, 12 hours 7 minutes ago

Caldwell Announces Leadership Appointments for Industrial Practice and Caldwell Analytics
Published on 07/16/2026 at 15:30, 12 hours 7 minutes ago

Resilient Energy Inc. Advances Commercial Rollout; Operations Enter Final Stage Ahead of Revenue Generation

View all ACCESSWIRE

Published on 07/17/2026 at 02:10, 1 hour 26 minutes ago

VARON Highlights Summer Wellness with Portable Oxygen Solutions for Active Lifestyles
Published on 07/16/2026 at 23:10, 4 hours 27 minutes ago

EQS-Adhoc: Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration
Published on 07/16/2026 at 21:16, 6 hours 21 minutes ago

Hertz Energy Advances Its Lake George Antimony-Tungsten Project and Summarizes Lithium Project
Published on 07/16/2026 at 20:59, 6 hours 38 minutes ago

EQS-Adhoc: SMA publishes preliminary results for the second quarter of 2026 and raises full-year 2026 guidance
Published on 07/16/2026 at 20:39, 6 hours 57 minutes ago

AUTODOC successfully optimises capital structure

View all EQS

Published on 07/16/2026 at 20:27, 7 hours 10 minutes ago

BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Published on 07/16/2026 at 18:08, 9 hours 28 minutes ago

Aéroports de Paris S.A - June and half-year 2026 traffic figures
Published on 07/16/2026 at 18:08, 9 hours 28 minutes ago

Aéroports de Paris S.A - Trafic du mois de juin et du 1er semestre 2026
Published on 07/16/2026 at 18:00, 9 hours 37 minutes ago

i2S Chiffre d'affaires S1 2026
Published on 07/16/2026 at 17:45, 9 hours 52 minutes ago

H1 2026 revenue: €6.1m (+14%)

View all LES ECHOS COMFI WIRE

News